Omburtamab
- Generic Name
- Omburtamab
- Drug Type
- Biotech
- CAS Number
- 1895083-75-6
- Unique Ingredient Identifier
- XQL6783S5T
Overview
CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).
Background
CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.